CASE REPORT Open Access

# Anaplastic transformation of thyroid cancer in mesentery metastases presenting as intestinal perforation: a case report



Kiyotaka Hosoda<sup>1</sup>, Kei Kusama<sup>1</sup>, Naoe Yanagisawa<sup>1</sup>, Taiichi Machida<sup>1</sup>, Akihito Nishio<sup>1</sup>, Shinji Nakata<sup>1</sup>, Ichiro Ito<sup>2</sup>, Masahide Watanabe<sup>2</sup> and Harutsugu Sodeyama<sup>1\*</sup>

#### **Abstract**

**Background:** Anaplastic thyroid carcinoma is a highly aggressive form of thyroid cancer associated with a very poor prognosis. Anaplastic transformation most commonly occurs in the thyroid itself or within regional lymph nodes. Here we report the case of a patient with papillary thyroid cancer, presenting with colon perforation as a result of anaplastic transformation of metastases in the mesentery tissue. There have been no previous reports of this form of anaplastic transformation.

Case presentation: A 74-year-old man was admitted to our hospital, presenting with abdominal pain that he had been experiencing for 1 week prior to admission. The patient had a history of papillary thyroid carcinoma, for which he underwent a total thyroidectomy and mediastinal lymph node dissection 6 years earlier, and subsequently received radioactive iodine therapy for postoperative recurrence in the lung 2 years later. During the present reported admission, a computed tomography scan revealed a large intra-abdominal mass infiltrating into the colon and retroperitoneum and also highlighted the pneumoperitoneum. The patient was diagnosed with generalized peritonitis as a result of colon perforation, as such, we conducted an emergency laparotomy. Intraoperative findings showed a mass affecting the ascending colon and kidney, following which, an ileostomy and biopsy were completed. Poorly differentiated spindle cells were identified in the biopsy specimens, and histopathological and immunohistochemical findings revealed the absence of thyroid carcinoma cells. The tumor was therefore believed to be a primary sarcoma. Following surgery, the patient recovered from sepsis that had arisen as a result of colon perforation, however, rapidly developed systemic metastases and died 1 month post-operation. An autopsy was performed, and the patient was diagnosed with anaplastic papillary thyroid cancer at the mesentery site of metastasis. This conclusion was reached owing to the presence of the squamous differentiation of lymph node cells, and because tumor cells were positive results for paired-box gene 8 expressions.

**Conclusions:** Anaplastic transformation of papillary thyroid carcinoma should be considered in the diagnosis of a large mesentery mass in patients with a history of papillary carcinoma. An appropriate biopsy and paired-box gene 8 immunostaining can be useful in confirming such a diagnosis.

**Keywords:** Anaplastic transformation, Peritoneal metastasis, Thyroid cancer, Intestinal perforation

<sup>&</sup>lt;sup>1</sup>Department of Surgery, Japanese Red Cross Society Nagano Hospital, 5-22-1 Wakasato, Nagano, Nagano 380-8582, Japan Full list of author information is available at the end of the article



<sup>\*</sup> Correspondence: s6x7c1@nagano-med.jp

#### **Background**


Papillary thyroid carcinoma is typically a slow-progressing cancer with high rates of recovery. Anaplastic transformation of these tumors, however, forms a highly aggressive variant of thyroid cancer, associated with a very poor prognosis [1]. Anaplastic transformation most commonly occurs in the thyroid itself or within regional lymph nodes, and in rare cases, developing in distant metastases [2]. No reports have demonstrated anaplastic transformation from mesentery metastasis previously. Here we report the case of a patient with papillary thyroid cancer, presenting with colon perforation as a result of anaplastic transformation in mesentery metastases.

#### **Case presentation**

A 74-year-old man was admitted to our hospital presenting with worsening abdominal pain he had been experiencing for 1 week prior to admission. The patient had a history of papillary thyroid carcinoma, pT4aN1bM0 stage I, for which he underwent a total thyroidectomy and mediastinal lymph node dissection 6 years earlier, and subsequently received radioactive iodine therapy for postoperative recurrence in the lung 2 years after the initial surgery. Upon admission, the patient's laboratory data revealed renal dysfunction (blood urea nitrogen: 36.3 mg/dL and creatinine: 2.99 mg/dL) and an elevated white blood cell count and C-reactive protein levels (191,600/µL and 30.78 mg/dL, respectively). A computed tomography (CT) scan showed a large intra-abdominal mass infiltrating into the colon and retroperitoneum (Fig. 1a) as well as the low-density area of the liver (Fig. 1b), peritoneal nodule (Fig. 1c), and lymphadenopathy in several paraaortic lymph nodes suggesting metastases or dissemination (Fig. 1d). Pneumoperitoneum was visible from the CT scan, suggesting colon perforation close to the tumor. The patient was diagnosed with generalized peritonitis as a result of colon perforation, as such, we conducted an emergency laparotomy. Intraoperative findings showed that the mass had invaded the ascending colon and right kidney. Due to the extensive spread of the mass, the single-stage operation was difficult to perform, and so a protective ileostomy was performed, and a biopsy was obtained. Histology of the biopsy identified poorly differentiated spindle cells, and histopathological and immunohistochemical findings revealed the absence of thyroid carcinoma cells in the specimen. The tumor was therefore believed to be a primary intraperitoneal or retroperitoneal undifferentiated sarcoma.

Following surgery, the patient recovered from sepsis that had arisen as a result of colon perforation and was indicated to undergo chemotherapy for sarcoma. However, systemic metastases developed rapidly (Fig. 1e, f) and his general condition deteriorated soon after recovering from sepsis. The patients died without any chemotherapy 1-month post-operation.

An autopsy was performed and identified the presence of tumors in the patient's mesentery tissue, brain, lungs, paraaortic lymph nodes, liver, small intestine, and bone marrow. In the tumor located in the mesentery, necrotic activity was identified; the tumor was grayish-white in color, measured  $18 \times 15 \times 10$  cm, and had invaded the ascending colon, forming a cavity in the tumor. The tumor was composed of pleomorphic spindle cells with eosinophilic cytoplasm and polymorphonuclear cell infiltration (Fig. 2a), and did not contain lymph node components. It is notable that squamous differentiation was identified in tumor cells of regional lymph nodes (Fig. 2b). Immunohistochemical staining for markers showed the presence of p16, CD56, chromogranin A, and



**Fig. 1** Computed tomography scan. Computed tomography shows a large intra-abdominal mass infiltrating into the colon and retroperitoneum (**a**, arrowhead) as well as the low-density area of the liver (**b**, arrowhead), peritoneal nodule (**c**, arrow), and lymphadenopathy in several paraaortic lymph nodes, suggesting metastases or dissemination (**d**, arrow). Pneumoperitoneum was visible, suggesting colon perforation near the tumor. Liver tumor, metastatic lymph node, and peritoneal dissemination were enlarged after 1 month (**e**, **f**, arrow, arrowhead)

Hosoda et al. Surgical Case Reports (2020) 6:194 Page 3 of 5




Fig. 2 Pathological findings of the autopsy samples. a Tumor composed of pleomorphic spindle cells with eosinophilic cytoplasm and polymorphonuclear cell infiltration. (Hematoxylin and eosin stain, × 20). b Tumor cells with squamous differentiation (arrow) in the regional lymph node. (Hematoxylin and eosin stain, × 20). c Cytokeratin AE1/AE3-positive lesion shows squamous differentiation (× 20). d PAX-8 sporadically positive in the atypical lesion (× 40). e Tumors in the lung reveal morphology of typical papillary thyroid carcinoma (arrowhead). (Hematoxylin and eosin stain, × 10)

synaptophysin and absence of p63, CD 10, caldesmon, transcription factor 1 (TTF-1), and thyroglobulin (Tg). These atypical mesenteric lesions also stained positive for cytokeratin AE1/AE3, exhibited squamous differentiation (Fig. 2c), and was sporadically positive for paired-box gene 8 (PAX-8) (Fig. 2d). MDM2 expression was not detected by fluorescence in situ hybridization. These findings suggest that this tumor was an undifferentiated carcinoma rather than a sarcoma. In addition, the tumors found in the lungs and brain had morphology that is typical of papillary thyroid carcinoma (Fig. 2e), with no other malignancies found. Based on these findings, the patient was diagnosed with anaplastic papillary thyroid cancer at a site of metastasis in the soft tissue of the mesentery.

#### Discussion

Papillary thyroid carcinoma is the most common type of malignant thyroid tumor, which typically progresses slowly and has an excellent prognosis [3]. While anaplastic transformation occurs in only 1–2% of malignant thyroid tumors, patients with these cancers have a dismal prognosis, with a median survival time of < 6 months [4, 5]. In anaplastic thyroid cancer patients with distant metastases (stage IVC), chemotherapy is the only treatment approach available. In chemotherapy regimens including doxorubicin or paclitaxel, over 50% of patients responded to the treatment; however, complete response was only observed in a few of these patients [6, 7]. The efficacy of molecular targeted drugs such as lenvatinib, a multi-tyrosine kinase inhibitor, has also been reported in recent years [8].

Anaplastic transformation most commonly occurs in the thyroid itself or within regional lymph nodes [9] and rarely develops at distant metastasis sites. Only 14 such cases were reported between 2000 and 2019; the characteristics of these cases are summarized in Table 1. Of these 14 patients, six were men (42.9%), eight were women (57.1%), and the median age of patients was 63.5 (range: 52-83) years. The time between primary diagnosis and anaplastic transformation ranged from 7-49 years. All patients died within 24 weeks (range: 2-24 weeks) of anaplastic transformation detection. The sites of anaplastic transformation included the submandibular region [10], liver [11], breast [12], retroperitoneum [13, 14], lung [2, 15, 16], shoulder [17], pelvis [18], mandible [19], and pleura [20, 21]; there have been no previous reports of anaplastic transformation occurring in the mesentery tissue. Furthermore, reports of mesentery metastases are rare in both papillary thyroid cancer and more common forms of anaplastic thyroid cancer [22, 23], making the patient's diagnosis in this case study an extremely rare and novel case.

In recent years, some reports have suggested that <sup>131</sup>I therapy, which is often administered to patients with recurrent papillary thyroid carcinoma, particularly in those with limiting tumor recurrence, can be associated with anaplastic transformation of papillary thyroid carcinoma [11, 24, 25]. In those reports, patients with anaplastic carcinomas were thought to have DNA damage induced by <sup>131</sup>I therapy and the combination of p53, a representative tumor suppressor gene, mutations, and DNA damage induced by <sup>131</sup>I therapy is reported to lead to anaplastic transformation [25]. Of the 14 patients

Hosoda et al. Surgical Case Reports (2020) 6:194 Page 4 of 5

**Table 1** Previous reports of anaplastic transformation of thyroid carcinoma developed from distant metastasis sites

Author	Year	Age	Sex	Location	Duration from primary diagnosis (years)	Immunostaining			<sup>131</sup>	Survival
						TTF-1	Tg	PAX-8	therapy	(weeks)
Sumida et al.	2000	60	Female	Submandibular region	7	N/A	N/A	N/A	None	20
Takeshita et al.	2008	81	Female	Liver	3	Negative	Focally	N/A	Yes	16
Angeles-Angeles et al.	2009	58	Female	Breast	20	Focally	Focally	N/A	Yes	N/A
Al-Qsous et al.	2010	83	Male	Lung	10	N/A	Weak	N/A	None	N/A
Sotome et al.	2010	82	Female	Retroperitoneum	18	Negative	Negative	N/A	Yes	2
Kaushal et al.	2011	52	Female	Shoulder	8	Positive	N/A	N/A	Yes	8
Nakayama et al.	2012	55	Female	Pelvis	12	Negative	Negative	N/A	Yes	14
Abe et al.	2014	61	Male	Lung	10	Positive	Negative	N/A	Yes	24
Solomon et al.	2015	64	Male	Retroperitoneum	28	Weak	Negative	Positive	Yes	3
Ambelil et al.	2016	76	Female	Mandible	7	Negative	Negative	Positive	Yes	N/A
Kim et al.	2017	61	Female	Pleura	19	Positive	Negative	Positive	None	16
Okuyama et al.	2017	63	Male	Lung	49	N/A	N/A	N/A	Yes	20
Capron et al.	2019	77	Male	Pleura	9	Negative	Negative	Positive	Yes	N/A
Present case	2020	77	Male	Mesentery	6	Negative	Negative	Positive	Yes	4

N/A not applicable

reported to have had anaplastic transformation at distant metastatic sites, 11 patients, including the patient in this case, had received <sup>131</sup>I therapy. Though this evidence is insufficient to suggest a causal relationship, these findings are suggestive of a correlation between <sup>131</sup>I therapy and anaplastic transformation.

In this case study, we considered the possibility of an anaplastic papillary carcinoma owing to the patient's history of recurrent papillary thyroid carcinoma. However, we could not confirm a diagnosis of anaplastic thyroid carcinoma at the time of operation, owing to histopathological and immunohistochemical findings indicating the absence of thyroid carcinoma markers in the tumor. The diagnosis of anaplastic papillary thyroid cancer could only be made with the detection of PAX-8 expression in a highly atypical lesion of the tumor located in the mesentery tissue as well as with the finding of the squamous differentiation of metastatic lymph node cells.

PAX-8 is a transcription factor involved in the process of cell differentiation in the thyroid, kidneys, and Müllerian duct. It is often expressed in thyroid cells even if an anaplastic transformation has occurred [26], whereas the expression of other thyroid-specific markers such as TTF-1 and Tg is often lost after anaplastic transformation [27]. This is also true for anaplastic transformation occurring in distant metastases. PAX-8 immunostaining is therefore valuable in the diagnosis of anaplastic thyroid cancers. In this case, we did not check PAX-8 expression because we thought that it will not contribute to the diagnosis since PAX-8 expression can be detected in different tumors other than thyroid tumor, such as

renal cancer. In hindsight, we should have checked PAX-8 immunostaining, as it would have led to the correct diagnosis.

However, it should be noted that such a disease is difficult to diagnose based only on the expression of PAX-8, and it is important to rule out other cancer types by histological examination or image-based findings. Moreover, in some cases, diagnoses are difficult to obtain, since biopsy specimens from several sites are requiring for histological examination or immunostaining before an accurate diagnosis can be confirmed. Obtaining biopsy samples from lymph nodes or other sites of metastasis can therefore be also helpful in diagnosing cases of anaplastic transformation.

#### Conclusions

Anaplastic transformation of papillary thyroid carcinoma can occur in mesentery sites of metastases. This disease should be considered in the diagnosis of a large mesentery mass in patients with a history of papillary carcinoma. The histological examination and PAX-8 immunostaining of multiple biopsies from the tumor or lymph nodes may be useful in the confirmation of this diagnosis.

#### Abbreviations

CT: Computed tomography; TTF-1: Transcription factor 1; Tg: Thyrogloblin; PAX-8: Paired-box gene 8

#### Acknowledgements

None.

#### Authors' contributions

All authors conceived the study concept and participated in interpretation of the results and writing of the report. Il and MW helped to evaluate pathological diagnosis. HS approved the final article. The authors read and approved the final manuscript.

#### **Funding**

None.

#### Availability of data and materials

All data generated during this study are included in this published article.

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Informed consent was obtained from this patient's family.

#### Competing interests

The authors declare no competing interests.

#### **Author details**

<sup>1</sup>Department of Surgery, Japanese Red Cross Society Nagano Hospital, 5-22-1 Wakasato, Nagano, Nagano 380-8582, Japan. <sup>2</sup>Department of Pathology, Japanese Red Cross Society Nagano Hospital, Nagano, Japan.

### Received: 21 May 2020 Accepted: 27 July 2020 Published online: 03 August 2020

#### References

- Untch BR, Olson JA Jr. Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid. Surg Oncol Clin N Am. 2006;15:661–79 x.
- Al-Qsous W, Miller ID. Anaplastic transformation in lung metastases of differentiated papillary thyroid carcinoma: an autopsy case report and review of the literature. Ann Diagn Pathol. 2010;14:41–3.
- Ito Y, Masuoka H, Fukushima M, Inoue H, Kihara M, Tomoda C, et al. Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy. World J Surg. 2010;34:1285–90.
- Wendler J, Kroiss M, Gast K, Kreissl MC, Allelein S, Lichtenauer U, et al. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol. 2016;175:521–9.
- Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg. 2012;36:1247–54.
- Bukowski RM, Brown L, Weick JK, Groppe CW, Purvis J. Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am J Clin Oncol. 1983:6:579–81.
- Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014;24:232–40.
- Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 2017;7:25.
- Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol. 1985;83:135–58.
- Sumida T, Hamakawa H, Imaoka M, Okamoto N, Takarada M, Tanioka H, et al. A case of submandibular malignant rhabdoid tumor transformed from papillary thyroid carcinoma. J Oral Pathol Med. 2001;30:443–7.
- Takeshita Y, Takamura T, Minato H, Misu H, Ando H, Yamashita T, et al. Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy. Intern Med. 2008;47:1709–12.
- Angeles-Angeles A, Chable-Montero F, Martinez-Benitez B, Albores-Saavedra
  J. Unusual metastases of papillary thyroid carcinoma: report of 2 cases. Ann
  Diagn Pathol. 2009;13:189–96.
- Sotome K, Onishi T, Hirano A, Nakamaru M, Furukawa A, Miyazaki H, et al. A
  rare case of anaplastic transformation within the metastatic site of the
  retroperitoneal region in a patient 17 years after total thyroidectomy for

- papillary carcinoma of the thyroid beginning with multiple bone metastases. Thyroid. 2007;17:1309–11.
- 14. Solomon JP, Wen F, Jih LJ. Anaplastic transformation of papillary thyroid cancer in the retroperitoneum. Case Rep Pathol. 2015;2015:241308.
- Abe T, Suzuki M, Shimizu K, Shinagawa N, Oizumi S, Matsuno Y, et al. Anaplastic transformation of papillary thyroid carcinoma in multiple lung metastases presenting with a malignant pleural effusion: a case report. J Med Case Rep. 2014;8:460.
- Okuyama C, Kimura M, Oda M, Kodani N, Aibe N, Yamazaki H. A case of thyroid papillary carcinoma: remarkable decrease in multiple lung metastases within 40 years after a single administration of radioiodine without thyroidectomy and with later anaplastic transformation. Case Rep Oncol. 2017;10:928–37.
- Kaushal S, Sharma MC, Mathur SR, Rastogi S, Bal CS, Chumber S. Anaplastic transformation of metastatic papillary thyroid carcinoma at shoulder mimicking soft tissue sarcoma. Indian J Pathol Microbiol. 2011;54:796–9.
- Nakayama R, Horiuchi K, Susa M, Hosaka S, Hayashi Y, Kameyama K, et al. Anaplastic transformation of follicular thyroid carcinoma in a metastatic skeletal lesion presenting with paraneoplastic leukocytosis. Thyroid. 2012;22:200–4.
- Ambelil M, Sultana S, Roy S, Gonzalez MM. Anaplastic transformation in mandibular metastases of follicular variant of papillary thyroid carcinoma: a case report and review of the literature. Ann Clin Lab Sci. 2016;46:552–6.
- Kim H, Park YW, Oh YH, Sim J, Ro JY, Pyo JY. Anaplastic transformation of papillary thyroid carcinoma only seen in pleural metastasis: a case report with review of the literature. Head Neck Pathol. 2017;11:162–7.
- Capron T, Giusiano S, Bourinet V, Laroumagne S, Dutau H, Astoul P.
   Anaplastic thyroid carcinoma mimicking a malignant pleural mesothelioma: clues for diagnosis. Thorac Cancer. 2019;10:2175–8.
- Benbassat CA, Mechlis-Frish S, Hirsch D. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg. 2006;30:1088–95.
- Besic N, Gazic B. Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. Thyroid. 2013;23:709–13.
- Sera N, Ashizawa K, Ando T, Ide A, Abe Y, Usa T, et al. Anaplastic changes associated with p53 gene mutation in differentiated thyroid carcinoma after insufficient radioactive iodine (131I) therapy. Thyroid. 2000;10:975–9.
- Shingu K, Kobayashi S, Yokoyama S, Fujimori M, Asanuma K, Ito KI, et al. The likely transformation of papillary thyroid carcinoma into anaplastic carcinoma during postoperative radioactive iodine-131 therapy: report of a case. Surg Today. 2000;30:910–3.
- Bishop JA, Sharma R, Westra WH. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol. 2011;42:1873–7.
- Vyas M, Harigopal M. Metastatic thyroid carcinoma presenting as malignant pleural effusion: a cytologic review of 5 cases. Diagn Cytopathol. 2016;44: 1085–9.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Submit your manuscript to a SpringerOpen journal and benefit from:

- ► Convenient online submission
- ► Rigorous peer review
- ► Open access: articles freely available online
- ► High visibility within the field
- ► Retaining the copyright to your article

Submit your next manuscript at ▶ springeropen.com